EGFR and neoplasm: One 1st-line/neoadjuvant trial using Dacomitinib (NCT0172833), a potent, irreversible kinase inhibitor of human EGFR/HER1, HER2 and HER4, has shown anti-tumor activity in N2-3 and M1 patients.